-
Determination of endometrial cancer molecular subtypes using a whole exome-sequencing based single-method approach
-
Integrated DNA Technologies and Molecular Health Ink Commercial Partnership
CORALVILLE, Iowa and HEIDELBERG, Germany (May 15, 2024)—Genomics solutions provider Integrated DNA Technologies (IDT) and Bio-IT company Molecular Health have entered into a global multi-year agreement, starting in the U.S., to integrate their next generation sequencing (NGS) capabilities. The partnership pairs IDT’s Archer NGS research assay platform with Molecular Health’s variant annotation and reporting software…
-
A multigene mutation classification of 468 colorectal cancers reveals a prognostic role for APC
-
Bioinformatory-assisted analysis of next-generation sequencing data for precision medicine in pancreatic cancer
-
Consolidated BRCA1/2 Variant Interpretation by MH BRCA Correlates with Predicted PARP Inhibitor Efficacy Association by MH Guide
-
Whole Exome Analysis to Select Targeted Therapies for Patients with Metastatic Breast Cancer – A Feasibility Study
-
Rewiring Drug Research and Development through Human Data-Driven Discovery (HD3)
-
Determination of the Cancer Genome Atlas (TCGA) Endometrial Cancer Molecular Subtypes Using the Variant Interpretation and Clinical Decision Support Software MH Guide
-
Currently no job listings
We are always looking for new talent. Feel free to send us your CV. We’d love to get to know you! careers@molecularhealth.com
-
Whole patient knowledge modeling of COVID-19 symptomatology reveals common molecular mechanisms
-
Advancing drug safety science by integrating molecular knowledge with post‐marketing adverse event reports
-
Evaluation of the TruSight Tumor 170 Assay and Its Value in Clinical Diagnostics
-
Application of a patient-centered reverse translational systems-based approach to understand mechanisms of an adverse drug reaction of immune checkpoint inhibitors
-
The COVID-19 explorer – An integrated, whole patient knowledge model of COVID-19 disease
-
Target adverse event profiles for predictive safety in the postmarket setting
-
A case study of a patient-centered reverse translational systems-based approach to understand adverse event profiles in drug development
